Cancer Genetics (NASDAQ:CGIX) and Avant Diagnostics (OTCMKTS:AVDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Risk and Volatility
Cancer Genetics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Avant Diagnostics has a beta of 10.7, indicating that its stock price is 970% more volatile than the S&P 500.
9.0% of Cancer Genetics shares are owned by institutional investors. Comparatively, 0.0% of Avant Diagnostics shares are owned by institutional investors. 21.3% of Cancer Genetics shares are owned by company insiders. Comparatively, 38.0% of Avant Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Cancer Genetics and Avant Diagnostics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Cancer Genetics and Avant Diagnostics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cancer Genetics currently has a consensus price target of $3.00, suggesting a potential upside of 1,150.52%. Given Cancer Genetics’ higher probable upside, analysts clearly believe Cancer Genetics is more favorable than Avant Diagnostics.
Earnings & Valuation
This table compares Cancer Genetics and Avant Diagnostics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cancer Genetics||$27.47 million||0.24||-$20.88 million||($0.67)||-0.36|
|Avant Diagnostics||$250,000.00||8.09||-$2.37 million||N/A||N/A|
Avant Diagnostics has lower revenue, but higher earnings than Cancer Genetics.
Cancer Genetics beats Avant Diagnostics on 6 of the 11 factors compared between the two stocks.
About Cancer Genetics
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
About Avant Diagnostics
Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.